3.28
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
Is ADC Therapeutics SA a good long term investmentHigh-yield market plays - PrintWeekIndia
What analysts say about ADC Therapeutics SA stockExceptional market performance - PrintWeekIndia
What drives ADC Therapeutics SA stock priceBreakout stock performance - jammulinksnews.com
ADC Therapeutics SA Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
ADC Therapeutics’ LOTIS-10 Study: A Potential Game-Changer in Lymphoma Treatment - TipRanks
What makes ADC Therapeutics SA stock price move sharplyCapital Growth Picks - Newser
Why ADC Therapeutics SA stock attracts strong analyst attentionFree Market Sentiment Analysis - Newser
How ADC Therapeutics SA stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2%What's Next? - MarketBeat
Adc Therapeutics Sa shares fall 1.88% after-hours as Sonnet Biotherapeutics, Inc. announces $888 million funding. - AInvest
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2% – Here’s Why - Defense World
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics (ADCT) Files Prospectus for Share Sale - GuruFocus
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? - Weekly Voice
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (NYSE:ADCT) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
ADC Therapeutics (ADCT) Price Target Lowered by RBC Capital | AD - GuruFocus
ADC Therapeutics price target lowered to $5 at RBC on growth outlook - Investing.com
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
Guggenheim Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):